Prof. Ajay Kumar Duseja
Designation : Professor & Head
Department : HEPATOLOGY
duseja.ajaykumar@pgimer.edu.in

 
 
 :: Contact Details
  Phone No.    :   7087009336
  Ext No.        :   6336
 :: Educational Qualification
  Graduation :   MBBS from HP University Shimla in year 1988
  Post Graduation :   MD (Internal Medicine) from HP University Shimla in year 1992
  Other Qualification.(1)      :   DM (Gastroenterology) from PGIMER Chandigarh in year 1996
  Other Qualification.(2)      :   FACG from American college of Gastroenterology in year 2007
  Other Qualification.(3)      :   FAMS from Fellow National Academy of Medical Scie in year 2016
  Other Qualification.(4)      :   FAASLD from Fellow- American Association for the Study of Liver Diseases in year 2017
     
 :: Area of Interest
       Area Of Interest       :

1.Nonalcoholic fatty liver disease (NAFLD)
2.Acute on Chronic Liver Failure
3.Viral hepatitis
4.HCC

     
 :: Research & Projects
      Extramural Projects       :

1. GS-US-384-1944- A phase 3 , Randomised, double blind, placebo controlled study evaluating the safety and efficacy of selonsertib in subjects with compensated cirrhosis due to non alcoholic steatohepatitis (NASH)

2. GS-US-384-1943 - A phase 3 , Randomised, double blind, placebo controlled study evaluating the safety and efficacy of selonsertib in subjects with compensated cirrhosis due to non alcoholic steatohepatitis (NASH) and F3 bridging fibrosis

3. GS-US-342-1521, “A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 weeks in Subjects with Chronic Hepatitis C Virus (HCV) infection

4. GS-US-334-1775, “A multicentre, prospective observational, post marketing surveillance study to evaluate the safety and efficacy of sofosbuvir- based regimens in clinical practice for the treatment of patients with chronic hepatitis C virus infection in India”.

5.A Prospective, multi-centre, double – blind, randomized trial of Saroglitazar 4mg vs Placebo in patients with Nonalcoholic steatohepatitis.

6. A cross-sectional, clinico-epidemiological, multicenter study to determine the prevalence of  nonalcoholic Fatty Liver disease and Thyroid dysfunction in patients with metabolic syndrome, visiting Endocrinology and Gastroenterology/Hepatology outpatient departments of tertiary health care centres in India.

7. Non-Invasive Assessment Of Disease Severity By Glycoproteomics In Patients With Nonalcoholic Fatty Liver Disease (NAFLD).

8. OPTIMIS - Outcomes of HCC patients treated with TACE followed or not followed by sorafenib and the influence of timing to initiate Sorafenib - non- interventional, post-authorization safety study

9. GS-US-334-0110:  “A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg Positive, Chronic Hepatitis B.”

10. GS-US-334-0108: “A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg Negative, Chronic Hepatitis B.”

11. GS-US-334-0116: “A Phase 3b, Multi-center, Randomized, open label, Study to Evaluate the Safety and Efficacy of Sofosbuvir plus Ribavirin in treatment-naïve adults with chronic Genotype 1 or 3 Hepatitis C Virus Infection.’’

12. Apolipoprotein C3 (APOC3) and patatin like phospholipase domain- containing protein 3 (PNPLA3) gene polymorphism and expression in patients with nonalcoholic fatty liver disease (NAFLD)

13. Diabetes – Liver Disease Embrace - “Comprehensive action for metabolic health and wellbeing-integration of a diabetes intervention with a liver health program”

14. A Case – Control study to investigate risk factors for Liver Cancer

15. Identification of single nucleotide polymorphisms in the transcriptional regulatory region of autophagy gene, ulk1 and their role in susceptibility to chronic hepatitis B virus infection.

16. Expression and polymorphism of toll like receptors (TLR) and small intestinal bacterial overgrowth in patients with nonalcoholic fatty liver disease (NAFLD)

17. Secondary Prophylaxis of hepatic encephalopathy: A double blind, randomized, placebo controlled study with supplementation with a probiotic preparation

18. Hepatitis C virus – The Indian Face

19. A Comparative study of Entacavir vs Adefovir plus Lamivudine vs Combination Entacavir plus Adefovir in lamivudine resistant Chronic Hepatitis B:Subject- The DEFINE STUDY

20. Supplementation with a probiotic preparation, VSL#3 as a support pharmaceutical therapy in cirrhotic patients for the treatment of minimal hepatic encephalopathy (MHE).  A double-blind, randomized, placebo controlled study”

 21. Small intestinal bacterial overgrowth and role of probiotic (VSL#3) in patients with nonalcoholic fatty liver disease

22. An open label, response adaptive study of Telbuvidine in adults with HBeAg positive compensated Chronic Hepatitis B

23. Role of cytokines and oxidative stress in patients with nonalcoholic steatohepatitis

24. Virological, Serological Tumor Markers and Serum Pro & Antiangiogenic Factors in the Spectrum of Chronic Liver Disease and Hepatocellular Carcinoma.
      Departmental / P.G.I.
      Projects      		 :

1.Prevalence and severity of nonalcoholicfatty liver disease in patients with coronary artery disease.

2.Long-term dynamic assessment of patients with acute-on-chronic liverfailure (ACLF) as defined by APASL, CANONIC and both definitions.

3.Utility of point shear wave elastography in prognosticating patientswith acute-on chronic-liver failure (ACLF)

4.Role of plasma exchange in patients with acute-on chronic-liver failure(ACLF)

5.Prevalence and risk factors of nonalcoholicfatty liver disease in HIV mono-infected patients

6.Comparison of patients with infection relatedACLF with acute hepatic insult related ACLF amongst patients with alcoholiccirrhosis

7.Immunological profile in patients with acute-on-chronic liver failure (ACLF) and decompensated cirrhosis of liver

8.Assessment of quality of life in patients with nonalcoholic fatty liver disease before and after treatment

9.Impaired renal functions in patients with Nonalcoholic Fatty Liver Disease.

10.Real Life study of directly acting anti viral drugs in patients with chronic hepatitis C.

11.Clinico-pathological profile of patients with acute on chronic liver failure (ACLF)

12.To study the correlation of visceral adipose tissue (VAT), metabolic syndrome and liver histology in patients with non alcoholic liver disease (NAFLD)

13.A cross sectional study of prevalence of atherosclerosis and cardiovascular disease risk factors in nonalcoholic fatty liver disease (NAFLD)

14.Correlation of Fibroscan with liver histology in patients with NAFLD and chronic viral hepatitis

15.Prevalence of obstructive sleep apnea (OSA) in patients of NAFLD, and the effect of OSA on severity of NAFLD

16.Randomized controlled trial of Vitamin D in patients with NAFLD

17.Impaired renal functions in patients with nonalcoholic fatty liver disease (NAFLD)

18.To correlate ICG clearance test with MELD score in patients with liver cirrhosis

19.Study on HBV specific T-cell responses in patients with hepatitis B virus infection

20.Diagnosis of minimal hepatic encephalopathy a comparison between psychometric hepatic encephalopathy score (PHES) and inhibitory control test (ICT)

21.Secondary prophylaxis of hepatic encephalopathy with probiotic VSL-3

22.To compare the model for end stage liver disease (MELD), child turcotte pugh (CTP) and cretinine modified child turcotte pugh  (crCTP) scores for predicting 3 months mortality in patients with cirrhosis of liver

23.Study of the outcome of radiological interventions in ruptured liver abscess

24.Extrapyramidal involvement in patients with cirrhosis liver

25.Correlation between degree and quality of sleep disturbance and the level of neuropsychiatric impairment in patients of cirrhosis: A cross-sectional study

26.Distribution of Hepatitis B Virus (HBV) Genotypes and Mutations in various HBV related liver disease

27.Study of prevalence of glucose intolerance in patients with cirrhosis

28.Inflammatory mediators and advanced MRI findings in patients with MHE

29.Spectrum of infections in patients with cirrhosis

30.Advanced MRI findings in patients with ACLF
      Area Of
      Specialization      		 :
Gastroenterology & Hepatology
      Future Plans       :
      Awards & Honours       :
1.ICMR Award -Received the prestigious ‘Dharamvir Datta Memorial Oration Award’ from the Indian Council of Medical Research for the year 2006 for research on “Nonalcoholic fatty liver disease in India’
2.ISG-Alkem Om Prakash Memorial Award-For the year 2006 by the Indian Society of Gastroenterology- for young gastroenterologist less than 40 years of age for contribution in research and publication
3.ISG- SR Naik Memorial Award- For the year 2008 by the Indian society of Gastroenterology for the best published work on nonalcoholic fatty liver disease in the year 2007-08
4.ISG-Zydus Oration Award (2013)-For the year 2013 by the Indian Society of Gastroenterology for the research h in the area of Nonalcoholic fatty liver disease (NAFLD)
5. Asia- Pacific International Fellowship-For 28th Asia- Pacific International Molecular Biology Network & Asian Molecular Biology Organization International course on ‘Innovative Strategy for Post Genomic Research- Integrated Functional analyses of Disease associated Sugar Chains and Proteins’ in May/June, 2005 at Graduate School of Medicine, Osaka University, Japan
6.Singapore Indian Group Networking for Empowerment Training: Fellowship to attend the training of trainers workshop in ‘Evidence based Medicine’, organized by Singapore Health services at Singapore in June 2009
7.Visiting scholar-For training in liver transplantation from May 1st to July 31st 2006, at the UNC center for Liver Diseases and Transplantation, University of North Carolina at Chapel Hill, USA
TRAVEL BURSARIES
1.ISG- APDW – Travel Fellowship-Indian Society of Gastroenterology travel fellowship to attend and present paper at the Asian Pacific Digestive week at Kuala Lumpur, Malaysia in September 2010
2.Korean society of Gastroenterology – Travel Award-Korean society of Gastroenterology – Travel Award for the paper ‘Serum leptin does not correlate with hepatic fibrosis in patients with nonalcohoilic fatty liver disease (NAFLD)’ at the Seoul International Digestive Disease Symposium (SIDDS) held at Seoul, Korea from Nov 22-22nd, 2007.
3.ISG- APDW – Travel Fellowship- Indian Society of Gastroenterology travel fellowship to attend and present paper at the 6th Asian Pacific Digestive week at Cebu City, Philippines in Nov 2006
BEST PAPER AWARDS   
ACG - Presidential Poster Award-Presidential poster award for the poster “Small intestinal Bacterial overgrowth and Toll like receptor signalling in patients with non-alcoholic fatty liver disease” in the annual conference of the American college of Gastroenterology (ACG) held at Honolulu, Hawaii, USA in October, 2015.
ISG – Plenary Award-Co-author and Principal Guide in the paper ‘Monocyte HLA-DR expression, neutrophil oxidative burst capacity and cytokine analysis in patients withdecompensated cirrhosis with and without acute-on chronic liver failure (ACLF)’ which received the First prize in the Annual Conference of the Indian Society of Gastroenterology (ISG) held at New Delhi in December, 2016.
INASL – Plenary Award-Co-author and Principal Guide in the paper ‘Histological severity in patients with nonalcoholic fatty liver disease is related to the volume of subcutaneous adipose tissue’ which received the second prize in the 19th Annual Conference of the Indian National association for the study of Liver (INASL) held at PGIMER, Chandigarh in March, 2011.
INASL – Plenary Award-Co-author and Principal Guide in the paper ‘Increase atherosclerosis and cardiovascular disease risk in patients with nonalcoholic fatty liver disease’ which received the third prize in the 18th Annual Conference of the Indian National association for the study of Liver (INASL) held at Bhubaneswar, in March, 2010.
ISG- Best Poster Award-Co-author in the best poster award for the poster, ‘Ultrastructure of mitochondria in patients with Nonalcoholic fatty liver disease’ at the annual conference of Indian Society of Gastroenterology (ISG) 2006.
ISG-Systopic oral - Best Paper Award-For the paper, ‘Insulin resistance in patients with chronic hepatitis C’ in annual conference of Indian Society of Gastroenterology (ISG) 2005
Prize from Prize from Indian Journal of Gastroenterology for the third best original article- For the paper ‘Assessment of insulin resistance and effect of metformin in nonalcoholic steatohepatitis- A preliminary report’ published in the journal in the year 2004. Duseja A, et al. Indian J Gastroenterol 2004; 23:12-15.
      Member Of Professional
      Bodies      		 :
FELLOW/MEMBERSHIPS OF SOCIETIES
1.Fellow - National Academy of Medical Sciences (FAMS)
2.Fellow – American Association for the Study of Liver diseases (FAASLD)
3.Fellow- American College of Gastroenterology (FACG)
4.Fellow - Society of Gastrointestinal Endoscopy of India (FSGEI)
5.Member – Asian Pacific Association for the study of the Liver (APASL)
6.Life member – Indian Society of Gastroenterology
7.Life member – Indian Association for the Study of liver
8.Life member – Indian Medical Association.
9.Life member – International Society of Non-communicable Diseases
10.Life member – Indian Society of Organ Transplantation (ISOT)

EDITORIAL BOARD ASSIGNMENTS
Editor/ Associate Editor (Present and Past)
1.Associate Editor – Journal of Clinical and Experimental Hepatology, An official journal of  the Indian National association for study of the Liver (INASL) (2016 onwards)
2.Associate Editor- JGH open (2016 onwards)
3.Section Editor (Hepatology Elsewhere) - Journal of Clinical and Experimental Hepatology  - (2011-14)
4.Editor - Elsevier Clinical Update Series (ECAB) series on NAFLD and ALD

Member Editorial Board (Present and Past)
1.Journal of Gastroenterology and Hepatology – Member Editorial Board
2.World Journal of Hepatology - Member Editorial Board
3.Euroasian Journal of Hepato-Gastroenterology - Member Editorial Board
4.Indian Journal of Gastroenterology - Member Editorial Board
5.Hepatitis B Annual journal - Member Editorial Board
6.Indian Clinical Updates (Gastroenterology) by Wiley Science - Member Editorial Board
7.Hepatology Communications - Member Editorial Board
8.International Journal of Noncommunicable disease (IJNCD) – Member Editorial Board

REVIEWER TO JOURNALS
1.Gastroenterology
2.Digestive Diseases and Sciences
3.Journal of Gastroenterology and Hepatology
4.Alimentary Pharmacology and Therapeutics
5.BMC Gastroenterology
6.Hepatology International
7.JGH Open
8.Diabetic Medicine
9.Annals of Hepatology
10.Saudi Journal of Gastroenterology
11.National Medical Journal of India
12.Indian Journal of Gastroenterology
13.Tropical Gastroenterology
14.Indian Journal of Community Medicine
15.Indian Journal of Medical Sciences
16.J of Clinical and Experimental Hepatology
17.Scientific Reports
     
 :: Publications(In Vancouver Style)
TOTAL PUBLICATIONS – 224 (INCLUDING 22 CHAPTERS IN A BOOK) Publications in National Journals - 90
1.Nampoothiri RV, Duseja A, Rathi M, et al. Renal Dysfunction in Patients With Nonalcoholic Fatty Liver Disease is Related to the Presence of Diabetes Mellitus and Severity of Liver Disease. J Clin Exp Hepatol. 2019;9:22-28.
2.Agrawal S, Rana BS, Mitra S, Duseja A, Das A, Dhiman RK, Chawla Y. A Case of Acute-on-Chronic Liver Failure (ACLF) Due to An Uncommon Acute And Chronic Event. J Clin Exp Hepatol. 2018; 1:95-97.
3.Sahu SK, Chawla YK, Dhiman RK, Singh V, Duseja A, Taneja S, Kalra N, Gorsi U. Rupture of Hepatocellular Carcinoma: A Review of Literature. J Clin Exp Hepatol. 2019 Mar-Apr;9(2):245-256.
4.Taneja S, Kumar P, Mitra S, Duseja A, Minz R, Das A et.al. Acute Exacerbation to Autoimmune Hepatitis Mimicking Acute Viral Hepatitis-A Case Series and Review of Literature. J Clin Exp Hepatol. 2018; 1:98-103.
5.Kalra N, Kang M, Duseja AK, Bhatia A, Singh V, Dhiman RK et.al. Comparison of radiofrequency ablation alone & in combination with percutaneous ethanol injection for management of hepatocellular carcinoma.Indian J Med Res. 2017 ;146 :S30-S37.
6.Gupta T, Dhiman RK, Ahuja CK, Agrawal S, Chopra M, Kalra N, Duseja A, Taneja S, Khandelwal N, Chawla Y. Characterization of Cerebral Edema in Acute-on-Chronic Liver Failure. J Clin Exp Hepatol. 2017 ;7(3):190-197.
7.Puri P, Saraswat VA, Dhiman RK, Anand AC, Acharya SK, Singh SP, Chawla YK, Amarapurkar DN, Kumar A, Arora A, Dixit VK, Koshy A, Sood A, Duseja A, Kapoor D, Madan K, Srivastava A, Kumar A, Wadhawan M, Goel A, Verma A, Shalimar, Pandey G, Malik R, Agrawal S.
Corrigendum to "Indian National Association for Study of the Liver (INASL) guidance for antiviral therapy against HCV infection: Update 2016" [J. Clin. Exp. Hepatol. 2016; 6:119-145.
8.Kumar P, Taneja S, Gupta K, Duseja A, Dhiman RK, Chawla YK. Unusual Presentation of Tubercular Liver Abscess in an Immune-Competent Adult. J Clin Exp Hepatol. 2017 ;1:77-79
9.Taneja S, Kumar P, Gautam V, Duseja A, Singh V, Dhiman RK, Chawla Y. Spontaneous Bacterial Peritonitis by Burkholderia cepacia Complex: A Rare, Difficult to Treat Infection in Decompensated Cirrhotic Patients. J Clin Exp Hepatol. 2017 ;2:102-106
10.Mehta M,  Satsangi S,  Duseja A, Taneja S,  Dhiman RK, Chawla Y. Can Alcoholic Liver Disease and Nonalcoholic Fatty Liver Disease Co-Exist? J Clin Exp Hepatol. 2017 ;2:121-126
11.Singhal M, Sinha U, Kalra N, Duseja A, Khandelwal N. Enucleation Sign: A Computed Tomographic Appearance of Ruptured Hepatocellular Carcinoma. J Clin Exp Hepatol. 2016; 6(4):335-336.
12.Taneja S, Tohra S, Duseja A, Dhiman RK, Chawla YK. Noninvasive Assessment of Liver Fibrosis By Transient Elastography and FIB4/APRI for Prediction of Treatment Response in Chronic Hepatitis C-An Experience from a Tertiary Care Hospital. J Clin Exp Hepatol. 2016; 6(4):282-290.
13.Taneja S, Kumar P, Duseja A, Singh V, Dhiman RK, Chawla Y. Honeycomb Cyst of the Liver. J Clin Exp Hepatol. 2016 Sep;6(3):250-251.
14.Taneja S, Borakokty A, Duseja A, Dhiman RK, Chawla Y. Acute Liver Failure Caused by Hepatitis A Virus with Dengue Coinfection. J Clin Exp Hepatol. 2016;6(2):164.
15.Duseja A, Singh SP, Saraswat VA, Acharya SK, Chawla YK, Chowdhury S, et al. Non-alcoholic Fatty Liver Disease and Metabolic Syndrome-Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of
Cardiology and Indian Society of Gastroenterology. J ClinExpHepatol. 2015; 5:51-68.
16.Puri P, Anand AC, Saraswat VA, Acharya SK, Dhiman RK, Sarin SK, Singh SP, Chawla YK, Aggarwal R, Amarapurkar D, Arora A, Dixit VK, Sood A, Shah S, Duseja A et.al. Indian National Association for Study of the Liver (INASL)
Guidance for Antiviral Therapy against HCV Infection in 2015. J Clin Exp Hepatol. 2015; 5:221-38.
17.Sachdev S, Mittal K, Patidar G, Marwaha N, Sharma RR, Duseja A, Chawla YK, Arora SK. Risk Factors for Transfusion Transmissible Infections Elicited on Post Donation Counselling in Blood Donors: Need to Strengthen Pre-donation Counselling. Indian J Hematol Blood Transfus. 2015; 31:378-84.
18.Duseja A. Staging of hepatocellular carcinoma. J Clin Exp Hepatol. 2014; 4:S74-9.
19.Kumar A, Acharya SK, Singh SP, Saraswat VA, Arora A, Duseja A et.al. The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations. J Clin Exp Hepatol. 2014; 4:S3-S26.
20.Dhiman RK, Saraswat VA, Valla DC, Chawla Y, Agarwal S, Duseja A et.al. Portal cavernoma cholangiopathy: consensus statement of a working party of the Indian national association for study of the liver. J Clin Exp Hepatol. 2014; 4:S2-S14.
21.Puri P, Anand AC, Saraswat VA, Acharya SK, Dhiman RK, Duseja A, et.al. Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part I: Status Report of HCV Infection in India. J Clin Exp Hepatol. 2014; 4:106-16.
22.Chinnaswamy S, Das K, Bairagya BB, Bhattacharyya C, Shalimar, Duseja A, Association of IL28 single nucelotide polymorphism rs8099917 with response to treatment in genotype 3 HCV infected patients from India.Trop gastroenterol  2014 ;35:96-102.
23.Agrawal S, Duseja A. Nonalcoholic Fatty Liver Disease--The Clinician's Perspective. Trop Gastroenterol. 2014; 35:212-21.
24.Duseja A. Combination Therapy in Severe Alcoholic Hepatitis—Doesn't Really Work. J Clin Exp Hepatol 2013; 3: 353-354
25.Duseja A, Dhiman RK, Chawla Y, Kalra N, Behera A,Giant hydatid cyst of the liver. Trop Gastroenterol. 2013 ;34:112-3
26.Kalra N, Ahuja CK, Duseja A, Chawla Y, Khandelwal N Endovascular management of RFA-induced hepatic arterial injury. Trop Gastroenterol. 2013 ;34:104-6
27.Duseja A. Portal Cavernoma Cholangiopathy—Clinical Characteristics. J Clin Exp Hepatol 2013; 4: S34-S36
28.Duseja A. Reversibility of Hepatic Fibrosis and Cirrhosis—Another Evidence. J Clin Exp Hepatol 2013; 3:167-168
29.Guleria A, Duseja A, Kalra N, Das A, Dhiman R, Chawla Y, Bhansali A. Patients with non-alcoholic fatty liver disease (NAFLD) have an increased risk of atherosclerosis and cardiovascular disease. Trop Gastroenterol. 2013; 34:74-82.
30.Kalra N, Kang M, Bhatia A, Duseja AK, Dhiman RK, Arya VK, Rajwanshi A, Chawla YK, Khandelwal N. Role of radiofrequency ablation in unresectable hepatocellular carcinoma: An Indian experience. Indian J Radiol Imaging. 2013; 23:139-44.
31.Duseja A, Choudhary NS, Gupta S Dhiman RK, Chawla YK, Sakhuja V. Treatment of Chronic hepatitis C in end stage renal disease: experience at a tertiary care centre. Trop Gastroenterol 2012;33:189-192
32.Kumar A, Sharma A, Duseja A, Das A, Dhiman RK, Chawla Y. Patients with Nonalcoholic Fatty Liver Disease (NAFLD) have Higher Oxidative Stress in Comparison to Chronic Viral Hepatitis. J Clin Exp Hepatol 2012:2:12-18
33.Menachery J, Chawla Y, Chakrabarti A, Duseja A, Dhiman R, Kalra N. Fungal liver abscess in an immunocompetent individual. Trop Gastroenterol. 2012; 33:232-3.
34.Gupta S, Chawla Y, Kaur J, Saxena R, Duseja A, Dhiman RK, Choudhary NS. Indocyanine green clearance test (using spectrophotometry) and its correlation with model for end stage liver disease (MELD) score in Indian patients with cirrhosis of liver. Trop Gastroenterol. 2012 ; 33:129-34.
35.Agrawal S, Duseja A. Non-alcoholic Fatty Liver Disease: East versus West. J Clin & Exp Hepatol 2012; 2: 122-134
36.Duseja A. Coffee and Liver – Long Way To Go. J Clin Exp Hepatol 2012; 2:291-294.
37.Duseja A. Interferon-Free Regimens for Chronic Hepatitis C—A Step Forward. J Clin Exp Hepatol 2012;3;76-78
38.Duseja A. It is Patatin - like Phospholipase Domain- Containing 3 gene (PNPLA3) – All the way. J Clin Exp Hepatol 2011; 2:94-96.
39.Chawla YK, Kashinath RC, Duseja A, Dhiman RK. Predicting Mortality Across a Broad Spectrum of Liver Disease—An Assessment of Model for End-Stage Liver Disease (MELD), Child–Turcotte–Pugh (CTP), and Creatinine-Modified CTP Scores. J Clin Exp Hepatol 2011; 1:161–168.
40.Garg A, Reddy C, Duseja A, Chawla YK, Dhiman RK. Association between Celiac Disease and Chronic Hepatitis C Virus Infection. J Clin Exp Hepatol 2011; 1: 41–44.
41.Rana  D, Menachery J, Chawla Y, Duseja A, Dhiman R, Arora S. HBV specific T-cell responses in hepatitis B. Tropical Gastroenterology 2011;32:273-278
42.Duseja A. Nonalcoholic fatty liver disease in India - a lot done, yet more required! Indian J Gastroenterol. 2010; 29:217-25
43.Sarma S, Sharma B, Chawla YK, Kapil S, Singla B, Kalra N, Behera A, Duseja A, Dhiman RK. Comparison of 7 staging systems in north Indian cohort of hepatocellular carcinoma. Trop Gastroenterol. 2010; 31:271-8.
44.Duseja A, Chawla Y. Treatment of HCV cirrhosis--simple or not quite so? Trop Gastroenterol. 2009; 30:183-5.
45.Duseja A, Dhiman RK, Chawla YK. Chronic hepatitis C and diabetes mellitus--are they related? Trop Gastroenterol. 2008; 29:121-2.
46.Kalra N, Vyas S, Lal A, Duseja A, Nijhawan R, Khandelwal N.  Biphasic multidetector CT of primary hepatic lymphoma in a patient with HIV infection. Trop Gastroenterol. 2008; 29:169-71.
47.Das A, Duseja A. Liver pathology in nonalcoholic fatty liver disease. Ann Natl  Acad Med Sci  2008;44:87-95
48.Duseja A:  Molecular Targets for Therapeutic Intervention in patients with Nonalcoholic Fatty Liver Disease. Ann Natl  Acad Med Sci   2007; 43:183-190.
49.Vaiphei K, Duseja A, Dutta U, Kochhar R.  Pain, jaundice and lump in a middle-aged man. Indian J Gastroenterol. 2007; 26:130-4.
50.Duseja A, Thumburu KK, Das A, Dhiman RK, Chawla YK, Bhadada S, Bhansali A.  Insulin tolerance test is comparable to homeostasis model assessment for insulin resistance in patients with nonalcoholic fatty liver disease. Indian J Gastroenterol. 2007; 26:170-3.
51.Duseja A, Kalra N, Chawla YK: Clinical Spectrum and Diagnosis of Nonalcoholic Fatty Liver Disease. Ann Natl  Acad Med Sci  2007; 43:167-182.
52.Duseja A, Thumburu KK, Das A, Dhiman RK, Chawla YK, Bhadada S, Bhansali A.  Insulin tolerance test is comparable to homeostasis model assessment for insulin resistance in patients with nonalcoholic fatty liver disease. Indian J Gastroenterol. 2007; 26:170-3.
53.Duseja A. Nonalcoholic fatty liver disease in India- Is it different? Trop Gastroenterol 2006 ;27:142-6
54.Punia RS, Arya S, Mohan H, Duseja A, Bal A. Spectrum of clinico-pathological changes in Barrett oesophagus. J Assoc Physicians India. 2006 ;54:187-9
55.Duseja A, Das A, Das R, Dhiman RK, Chawla Y, Bhansali A. Unconjugated hyperbilirubinemia in nonalcoholic steatohepatitis – Is it Gilbert’s syndrome? Tropical Gastroenterology 2005;26:123-25
56.Duseja A, Chawla Y. Nonalcoholic fatty liver disease in India- How much? How soon? Tropical Gastroenterology 2005;26: 1-3
57.Duseja A, Dhiman RK. Nonalcoholic fatty liver disease. Gastroenterology Today 2005;9:145-149
58.Duseja A, Murlidharan R, Bhansali A, Sharma S, Das A, Das R, Chawla Y. Assessment of insulin resistance and effect of metformin in nonalcoholic steatohepatitis- A preliminary report. Indian J Gastroenterol 2004; 23:12-15
59.Duseja A, Sharma S, Das K, Dhiman RK, Chawla YK. Is vaccination against hepatitis A virus required in patients with cirrhosis of the liver? Trop Gastroenterol 2004;25:162-3
60.Nitin, Radhika S, Duseja A, Rajvanshi A, Gupta SK, Sehgal S, Suri S, Chawla Y. Clinico-cytopathological spectrum of  hepatocellular carcinoma, its correlation with serum alfa feto protein level, and Hepatitis B and C viral markers. Trop Gastroenterol 2004; 25:116-120.
61.Vaiphei K, Duseja A, Dash RJ, et al. A case of chronic alcoholic who presented with fever. Gastroenterology Today 2004; 8:66-71
62.Duseja A, Mohit Nanda, Ashim Das, Reena Das, Anil Bhansali, Yogesh Chawla. Prevalence of obesity, diabetes mellitus and hyperlipidemia in patients with cryptogenic liver cirrhosis. Trop Gastroenterol 2004; 25:15-17.
63.Duseja A, Sharma S, Subrnamanian PG, Agnihotri SK, Chakraborti A, Chawla Y. Occult hepatitis B virus (HBV) infection in healthy blood donors. Indian J Pathol Microbiol 2003; 46:690-2.
64.Chawla Y, Duseja A. What is the assocation between helicobacter pylori and hyperammonemia in liver disease? Indian J Gastroenterol 2003;22:207-8
65.Sachdev A, Duseja A. Decompressive shunts and hepatic encephalopathy. Indian J Gastroenterol 2003;22:S21-s24
66.Duseja A, A Sachdev, RK Dhiman, YK Chawla. Helicobacter pylori and hepatic encephalopathy.  Indian J Gastroenterol 2003;22:S31-S32
67.Duseja A, RK Dhiman, VA Saraswat, YK Chawla. Minimal hepatic encephalopathy: natural history, impact on daily functioning and role of treatment. Indian J Gastroenterol 2003;22:S42-S44
68.Sachdev A, Duseja A, Bhalla A, Handa U, Sandhu BS, Gupta V, Kochhar S. Efficacy of endoscopic wire guided biliary brushings in the evaluation of biliary strictures. Trop Gastroenterol 2003;24:215-217
69.Duseja A, Nada R, Kalra N, Acharya SK, Minz M, Joshi K, Chawla Y. Fibrosing cholestatic hepatitis like syndrome in a hepatitis B virus and hepatitis C virus negative renal transplant recipient: a case report with autopsy findings.  Trop Gastroenterol 2003;24:31-4
70.Duseja A, Dhiman RK. Nonalcoholic steatohepatitis (NASH) – How much fat in Indian livers? Bull PGI 2003; 37:44-47.
71.Chawla Y, Duseja A. Noncirrhotic portal fibrosis (NCPF) is a vanishing disease in India. Trop Gastroenterol 2003;24:45-6
72.Nada R, Duseja A, Sachdev A, Mohan H. Comparative analysis of duodenal biopsy tissue orientation supported on vegetable matrix versus filter paper. Indian J Gastroenterol. 2002; 21:110-2
73.Duseja A, Arora L, Masih B, Singh H, Gupta A, Behera D, Chawla YK, Dhiman RK. Hepatitis B and C virus--prevalence and prevention in health care workers. Trop Gastroenterol. 2002; 23:125-6
74.Bhalla A, Singh R, Sachdev A, D'Cruz S, Duseja A. Circadian pattern in cerebro vascular disorders. Neurol India. 2002; 50:526-7.
75.Haqiqat Singh, B Masih, SK Satpathy, Duseja A, YK Chawla. Financial burden of alcohol abuse in patients with alcoholic liver disease. Trop Gastroenterol 2001; 22:172
76.Radotra BD, Duseja A, Ashim Das, K Singh, RJ Dash. Hepatic angiosarcoma simulating cirrhosis of the liver. Bull PGI 2001; 35: 127-38
77.Duseja A, YK Chawla. What is rifampicin doing in Pruritus of Cholestasis?  Trop Gastroenterol 2001; 22:123-4
78.Duseja A, RK Dhiman. Endoscopic management of variceal bleed. Gastroenterology Today 2001; 5: 80-4
79.Duseja A, YK Chawla. Pregnancy and liver disease. Gastroenterology Today 2001; 5: 141-4
80.Duseja A. Review of endoscopy journals. Endoscope 2001; 4: 7-12
81.Duseja A, Atul Sachdev, A Kumar et al. Periampullary carcinoma presenting as prolonged pyrexia. Trop Gastroenterol 2000; 21:127-28.
82.Nada R, Duseja A, P Dey. Fine needle aspiration cytology of Gastrointestinal Carcinoid tumors. Journal of Cytology 2000; 17:167-172.
83.Duseja A, RK Dhiman. Drug induced hepatotoxicity. Drug Bulletin PGIMER 2000; 24: 16-34
84.Duseja A, Atul Sachdeva, HS Malhotra. Endoscopic removal of needles from duodenum. Indian J Gastroenterol. 1999; 18:19.
85.Singh V, Duseja A, A Kumar et al. Baloon Dilatation in Achalasia Cardia. Trop Gastroenterol 1999; 20:68-69.
86.Duseja A, RK Dhiman, Kapil Bhargava et al. Treatment of Budd-Chiari Syndrome by percutaneous transluminal angioplasty Bull, PGI 1999; 33:75-78
87.Duseja A, RK Dhiman, Y Chawla et al. Cysto-bilio-bronchial communication in a hydatid cyst of liver. Trop Gastroenterol 1997:10; 30-31.
88.Dhiman RK, Duseja A. Managing Gastro oesophageal Reflux Disease. Gastroenterology Today. 1997:1; 81-85
89.Dhiman RK, Duseja A. Extrahepatic Portal Venous Obstruction. Bombay Hospital Journal, 1996:38; 741-745
90.Dhiman RK, Duseja A. Budd-Chiari Syndrome. Bombay Hospital Journal. 1996:38; 746-752
Publications in International Journals - 112
1.Duseja A, Najmy S, Sachdev S, Pal A, Sharma RR, Marwah N, Chawla Y. High prevalence of non-alcoholic fatty liver disease among healthy male blood donors of urban India. JGH Open. 2019 Jan 16;3(2):133-139.
2.Sood A, Duseja A, Kabrawala M, et al. Sofosbuvir-velpatasvir single-tablet regimen administered for 12 weeks in a phase 3 study with minimal monitoring in India. Hepatol Int. 2019; 13:173-179.
3.Chan WK, Treeprasertsuk S, Goh GB, Fan JG, Song MJ, Charatcharoenwitthaya P, Duseja A, et al. Optimizing Use of Nonalcoholic Fatty Liver Disease Fibrosis Score, Fibrosis-4 Score, and Liver Stiffness Measurement to Identify Patients with Advanced Fibrosis. Clin Gastroenterol Hepatol. 2019 Mar 12. [Epub ahead of print]
4.Kumar S, Kapoor R, Oinam AS, Kalra N, Duseja A. Role of stereotactic body radiation therapy in liver metastasis: A pilot study from tertiary cancer institute in India. J Cancer Res Ther. 2019; 15:169-175.
5.Kalra N, Gupta P, Gorsi U, Bhujade H, Chaluvashetty SB, Duseja A, et al. Irreversible Electroporation for Unresectable Hepatocellular Carcinoma: Initial Experience. Cardiovasc Intervent Radiol. 2019, Jan 29 [Epub ahead of print]
6.Younossi ZM, Stepanova M, Ong J, Yilmaz Y, Duseja A, Eguchi Y, et al. ; Global NASH Council. Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients with Non-alcoholic and Alcohol-Related Fatty Liver Disease. Clin Gastroenterol Hepatol. 2018 Nov 23. [Epub ahead of print]
7.Shukla J, Kalra N, Kumar R, Bhusari P, Chhabra A, Parmar M, Vatsa R, Singh H, Duseja A, Mittal BR. Two Cases of 188Re Microspheres for Inoperable,Hepatocellular Carcinoma. Clin Nucl Med. 2018 Nov 10.[Epub ahead of print]
8.Molnar MZ, Joglekar K, Jiang Y, Cholankeril G, Abdul MKM, Kedia S, Gonzalez,HC, Ahmed A, Singal A, Bhamidimarri KR, Aithal GP, Duseja A, Wong VW, Gulnare A, Puri P, Nair S, Eason JD, Satapathy SK; Global NAFLD Consortium. Association of Pre-Transplant Renal Function with Liver Graft and Patient
 Survival after Liver Transplantation in Patients with Nonalcoholic Steatohepatitis. Liver Transpl. 2018 Oct 28. [Epub ahead of print]
9.Verma N, Singh S, Taneja S, Duseja A, Singh V, Dhiman RK, Chakrabarti A, Chawla YK. Invasive fungal infections amongst patients with acute-on-chronic liver failure at high risk for fungal infections. Liver Int. 2018 Oct 1. [Epub ahead of print]
10.Dhiman RK, Grover GS, Premkumar M, Taneja S, Duseja A, Rathi S, Satsangi S. Direct-acting antiviral Therapy Is Safe and Effective in Pediatric Chronic Hepatitis C: The Public Health Perspective. J Pediatr Gastroenterol Nutr. 2018; 11. [Epub ahead of print]
11.Dhillon BK, Chopra G, Jamwal M, Chandak GR, Duseja A, Malhotra P, Chawla YK,Garewal G, Das R. Adult onset hereditary hemochromatosis is associated with a novel recurrent Hemojuvelin (HJV) gene mutation in north Indians. Blood Cells Mol Dis. 2018 ; 73:14-21.
12.Anand L, Choudhury A, Bihari C, Sharma BC, Kumar M, Maiwall R, Tan SS, Shah ,SR, Hamid S, Butt AS, Jafri W, Chawla YK, Taneja S, Duseja A, Dhiman RK, Mahtab,MA, Ghazinyan H, Duan Z, Chen Y, Shukla A, Hu J, Abbas Z, Treeprasertsuk S,Lesmana LA, Lesmana CR, Sollano JD, Carpio G, Sahu MK, Kumar G, Sarin SK; APASL ACLF (AARC) working party.
Flare of Autoimmune Hepatitis causing acute on chronic liver failure (ACLF): diagnosis and response to corticosteroid therapy.Hepatology. 2018; 16. [Epub ahead of print]
13.Satsangi S, Duseja A, Sachdeva M, Tomer S, Arora SK, Taneja S, Dhiman RK,Chawla YK. Monocyte human leukocyte antigen - Antigen D related, neutrophiloxidative burst and cytokine analysis in patients of decompensated cirrhosis with and without acute-on chronic liver failure. PLoS One. 2018 ; 13(7):e0200644.
14.Younossi Z, Stepanova M, Ong JP, Jacobson IM, Bugianesi E, Duseja A, Eguchi Y,Wong VW, Negro F, Yilmaz Y, Romero-Gomez M, George J, Ahmed A, Wong R, Younossi I, Ziayee M, Afendy A; Global Nonalcoholic Steatohepatitis Council. Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular
Carcinoma in Liver Transplant Candidates. Clin Gastroenterol Hepatol. 2018;14. [Epub ahead of print] .
15.Prinja S, Bahuguna P, Duseja A, Kaur M, Chawla YK. Cost of Intensive Care Treatment for Liver Disorders at Tertiary Care Level in India. Pharmacoecon Open. 2018 ;2:179-190.
16.Taneja S, Duseja A, De A, Mehta M, Ramachandran R, Kumar V, Kohli HS, Gupta,KL, Dhiman RK, Chawla Y. Low-Dose Sofosbuvir Is Safe and Effective in Treating Chronic Hepatitis C in Patients with Severe Renal Impairment or End-Stage Renal Disease. Dig Dis Sci. 2018 ;63:1334-40.
17.Sakpal M, Satsangi S, Mehta M, Duseja A, Bhadada S, Das A, Dhiman RK, Chawla YK. Vitamin D supplementation in patients with nonalcoholic fatty liver disease: A randomized controlled trial. JGH Open. 2018 ;2:62-67.
18.Verma N, Kumar P, Mitra S, Taneja S, Dhooria S, Das A, Duseja A, Dhiman RK,Chawla Y. Drug idiosyncrasy due to pirfenidone presenting as acute liver failure:Case report and mini-review of the literature. Hepatol Commun. 2017 Dec 27;2:142-147.
19.Taneja S, Borkakoty A, Rathi S, Kumar V, Duseja A, Dhiman RK, Gupta KL, Chawla Y. Assessment of Liver Fibrosis by Transient Elastography Should Be Done After Hemodialysis in End Stage Renal Disease Patients with Liver Disease. Dig Dis Sci.2017 ;11:3186-3192.
20.Taneja S, Kumar P, Rathi S, Duseja A, Singh V, Dhiman RK, Chawla YK. Acute Liver Failure Due to Etodolac, a Selective Cycloxygenase- 2 (COX -2) InhibitorNon-Steroidal Anti-Inflammatory Drug Established by RUCAM-Based Causality Assessment. Ann Hepatol. 2017 ;5:818-821
21.Taneja S, Duseja A, De A, Kumar V, Ramachandran R, Sharma A, Dhiman RK, Gupta KL, Chawla Y. Successful treatment of chronic hepatitis C infection with directly acting antivirals in renal transplant recipients. Nephrology (Carlton). 2018; 9: 876-882.
22.Chitturi S, Wong VW, Chan WK, Wong GL, Wong SK, Sollano J, Ni YH, Liu CJ, Lin YC, Lesmana LA, Kim SU, Hashimoto E, Hamaguchi M, Goh KL, Fan J, Duseja A et.al. The Asia-Pacific Working Party on Nonalcoholic Fatty Liver Disease Guidelines 2017 Part 2: Management and special groups. J Gastroenterol Hepatol. 2018 ; 1: 86-98.
23.Wong VW, Chan WK, Chitturi S, Chawla Y, Dan YY, Duseja A et.al. The Asia-Pacific Working Party on Nonalcoholic Fatty Liver Disease Guidelines 2017 Part 1: Definition, risk factors and assessment. J Gastroenterol Hepatol. 2018;1:70-85.
24.Sharma K, Gupta N, Goyal K, Duseja A, Sharma A, Rajwanshi A. Evaluation of polymerase chain reaction in space-occupying lesions of liver reported as granulomatous inflammation/tuberculosis on fine-needle aspiration cytology. Cytojournal. 2017; 14:1.
25.Choudhary NS, Saraf N, Saigal S, Duseja A, Gautam D, Lipi L, Rastogi A, Goja S, Bhangui P, Ramchandra SK, Babu YR, Soin AS. Prediction of nonalcoholic fatty liver in prospective liver donors. Clin Transplant. 2017; 4 .
26.Shah SR, Chowdhury A, Mehta R, Kapoor D, Duseja A, Koshy A, et al. Sofosbuvir plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 or 3 infection in India. J Viral Hepat. 2017;5:371-379.
27.Randhawa R, Duseja A, Changotra H. A novel Tetra-primer ARMS-PCR based assay for genotyping SNP rs12303764(G/T) of human Unc-51 like kinase 1 gene. Mol Biol Rep. 2017; 44:1-4.
28.Kapil S, Duseja A, Sharma BK, Singla B, Chakraborti A, Das A, Ray P, Dhiman RK, Chawla Y. Genetic polymorphism in CD14 gene, a co-receptor of TLR4 associated with non-alcoholic fatty liver disease. World J Gastroenterol. 2016;42:9346-9355.
29. Satsangi S, Mehta M, Duseja A, Taneja S, Dhiman RK, Chawla Y. Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C. J Gastroenterol Hepatol. 2017; 4:859-863.
30.Singhal R, Alhawat R, Tiwari P and Duseja A. Efficacy and Safety of Sofosbuvir with Simeprevir in Hepatitis C Infected Patients with Severe Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Biology, Engineering, Medicine and Science Reports, 2016; 2:05-12.
31.Tomer S, Chawla YK, Duseja A, Arora SK. Dominating expression of negative regulatory factors downmodulates major histocompatibility complex Class-II expression on dendritic cells in chronic hepatitis C infection. World J Gastroenterol. 2016; 22:5173-82.
32.Das A, Trehan A, Duseja AK, Bansal D. High Seroprevalence of Hepatitis B in Children with Cancer in India is Not Related to Transfusions or Hospital Admissions. Pediatr Blood Cancer. 2016; 9:1680-1.
33.Kapil S, Duseja A, Sharma BK, Singla B, Chakraborti A, Das A, Ray P, Dhiman RK, Chawla Y. Small intestinal bacterial overgrowth and toll-like receptor signaling in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2016; 31:213-21.
34.Agrawal S, Duseja A, Aggarwal A, Das A, Mehta M, Chawla Y et.al. Obstructive sleep apnea is an important predictor of hepatic fibrosis in patients with nonalcoholic fatty liver disease in a tertiary care center. Hepatol Int. 2015; 9:283-91.
35.Das A, Trehan A, Duseja A, Bansal D. High Seroprevalence of Hepatitis B in Children with Cancer in India is Not Related to Transfusions or Hospital Admissions. Pediatr Blood Cancer. 2016; 63: 1680-81.
36.Ramanathan S, Khandelwal N, Kalra N, Bhatia A, Dhiman RK, Duseja A, Chawla YK. Correlation of HVPG level with ctp score, MELD Score, ascites, size of varices, and etiology in cirrhotic patients. Saudi J Gastroenterol. 2016; 22:109-15.
37.Shalimar, Saraswat V, Singh S, Duseja A, Shukla A, Eapen CE, Kumar D, Pandey G, Venkataraman J, Narayanswami K, Puri P, Dhiman RK, Thareja S, Nijhawan S, Bhatia S, Zachariah U, Sonika U, Thomas V, Acharya SK. Acute on chronic liver failure in India: the INASL Consortium experience. J Gastroenterol Hepatol. 2016 ;10:1742-1749.
38.Bose PP, Mandal G, Kumar D, Duseja A, Chatterjee BP. Visual detection of serum asialohaptoglobin by plasmonic sandwich ELLSA - a new platform for cirrhosis diagnosis. Analyst. 2016; 141:76-84.
39.Ranga U, Kalra N, Saxena AK, Bhatia A, Sandhu MS, Duseja AK, Chawla YK, Khandelwal N.Focal hepatic lesions characterisation by different sonographic techniques: a prospective analysis. J Ultrasound. 2015; 19:15-23.
40.Rai R, Ahuja CK, Agrawal S, Kalra N, Duseja A, Khandelwal N, Chawla Y, Dhiman RK. Reversal of Low-Grade Cerebral Edema after Lactulose/Rifaximin Therapy in Patients with Cirrhosis and Minimal Hepatic Encephalopathy. Clin Transl Gastroenterol. 2015 ;17.
41.Singla B, Bhattacharyya R, Chakraborti A, Sharma BK, Kapil S, Chawla YK, Arora SK, Das A, Dhiman RK, Duseja A. Response to potent anti-HBV agents in chronic hepatitis B and combined effect of HBV reverse transcriptase mutations. Gene. 2015; 567:22-30.
42.Taneja S, Sakpal M, Ranjan R, Duseja A, Dhiman PK, Chawla YK. Hepatology: Hepato splenic sarcoidosis presenting as cholestatic jaundice and severe constitutional symptoms mimicking malignancy. J Gastroenterol Hepatol. 2015; 30:968.
43.Randhawa R, Sehgal M, Singh TR, Duseja A, Changotra H. Unc-51 like kinase 1 (ULK1) in silico analysis for biomarker identification: A vital component of autophagy. Gene. 2015; 562:40-9.
44.Dhiman RK, Rana B, Khattri A, Malhotra S, Duseja A, Chawla YK.et.al. Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial. Gastroenterology. 2014 ;147:1327-37
45.Dhiman RK, Agrawal S, Gupta T, Duseja A, Chawla Y. Chronic Liver Failure-Sequential Organ Failure Assessment is better than the Asia-Pacific Association for the Study of Liver criteria for defining acute-on-chronic liver failure and predicting outcome. World J Gastroenterol. 2014; 20:14934-41.
46.Agrawal S, Duseja A, Gupta T, Dhiman RK, Chawla Y.Simple Organ Failure Count Versus Canonic Grading System for Predicting Mortality in Acute on Chronic Liver Failure. J Gastroenterol Hepatol. 2014; 30:575-81.
47.Umapathy S, Dhiman RK, Grover S, Duseja A, Chawla YK.Persistence of cognitive impairment after resolution of overt hepatic encephalopathy. Am J Gastroenterol. 2014 ;109:1011-9
48.Singla B, Chakraborti A, Sharma BK, Kapil S, Chawla YK, Arora SK, Das A, Dhiman RK, Duseja A. Levels of hepatitis B virus replicative intermediate in serum samples of chronic hepatitis B patients Mol Biol Rep. 2014 ;41:4689-96.
49.Duseja A, Chawla YK. Obesity and NAFLD: the role of bacteria and microbiota. Clin Liver Dis. 2014; 18:59-71.
50.Thumburu KK, Dhiman RK, Vasishta RK, Chakraborti A, Butterworth RF, Beauchesne E, Desjardins P, Goyal S, Sharma N, Duseja A, Chawla Y. Expression of astrocytic genes coding for proteins implicated in neural excitation and brain edema is altered after acute liver failure. J Neurochem. 2014 ;128:617-27
51.Duseja A, Chalasani N. Epidemiology and risk factors of non-alcoholic fatty liver disease (NAFLD). Hepato Int 2013; 7: S755 – S764.
52.Sharma BK, Srinivasan R, Kapil S, Singla B, Chawla YK, Chakraborti A, Saini N, Duseja A, Das A, Kalra N, Dhiman RK. Angiogenic and anti-angiogenic factor gene transcript level quantitation by quantitative real time PCR in patients with hepatocellular carcinoma. Mol Biol Rep. 2013 ; 40:5843-52
53.Aggarwal A, Sharma V, Vaiphei K, Duseja A, Chawla YK. An unusual cause of cholestatic hepatitis: syphilis. Dig Dis Sci. 2013; 58:3049-51.
54.Singla B, Chakraborti A, Sharma BK, Kapil S, Chawla YK, Arora SK, Das A, Dhiman RK, Duseja A. Hepatitis B virus reverse transcriptase mutations in treatment Naïve chronic hepatitis B patients. J Med Virol. 2013; 85:1155-62.
55.Duseja A, Choudhary NS, Gupta S, Dhiman RK, Chawla Y. APACHE II score is superior to SOFA, CTP and MELD in predicting the short-term mortality in patients with acute-on-chronic liver failure (ACLF). J Dig Dis. 2013 ;14:484-90
56.Samanta J, Dhiman RK, Khatri A, Thumburu KK, Grover S, Duseja A, Chawla Y. Correlation between degree and quality of sleep disturbance and the level of neuropsychiatric impairment in patients with liver cirrhosis. Metab Brain Dis. 2013; 28:249-59.
57.Sharma BK, Srinivasan R, Kapil S, Singla B, Saini N, Chawla YK, Chakraborti A, Duseja A, Kalra N, Dhiman RK Serum levels of angiogenic and anti-angiogenic factors: their prognostic relevance in locally advanced hepatocellular carcinoma. Mol Cell Biochem. 2013; 383:103-12. 
58.Duseja A, Chawla Y. Portal hypertension in nodular regenerative hyperplasia: a mixed bag! J Gastroenterol Hepatol. 2012; 27:1260-2.
59.Duseja A, Aggarwal R. APOC3 and PNPLA3 in Non-alcoholic Fatty Liver Disease (NAFLD) - Need to Clear the Am. J Gastroenterol Hepatol. 2012; 27:848-51.
60.Choudhary NS, Duseja A, Kalra N, Das A, Dhiman RK, Chawla YK.  Correlation of adipose tissue with liver histology in Asian Indian patients with nonalcoholic fatty liver disease (NAFLD). Ann Hepatol. 2012; 11:478-86.
61.Rana D, Duseja A, Dhiman RK, Chawla Y and Arora SK. Maturation defective myeloid dendritic cells in nonalcoholic fatty liver disease patients release inflammatory cytokines in response to endotoxin.  Hepatol Int 2012; 7:562-9.
62.Rana D, Chawla YK, Duseja A, Dhiman R, Arora SK. Functional reconstitution of defective myeloid dendritic cells in chronic hepatitis C infection on successful antiviral treatment. Liver Int. 2012 ;32:1128-37
63.Choudhary NS, Gupta S, Chawla YK, Duseja A, Dhiman RK, Das A. Azathioprine induced liver injury: a case report. Dig Dis Sci. 2012; 57:1717-8.
64.Guru Murthy GS, Rana BS, Das A, Thapa BR, Duseja A, Dhiman RK, Chawla YK. Alagille syndrome: a rare disease in an adolescent. Dig Dis Sci. 2012; 57:3035-7.
65.Rao N, Bodh V, Duseja A, Singh V, Chawla YK. Cyanoacrylate glue: a bedside treatment for post paracentesis ascitic leak in patients with tense ascites. Dig Dis Sci. 2012; 57:2231-2.
66.Savlania A, Behera A, Vaiphei K, Singh H, Dhiman RK, Duseja A, Chawla YK. Primary leiomyosarcoma of gallbladder: a rare diagnosis. Case Rep Gastrointest Med. 2012; 2012:287012.
67.Kaman L, Nusrath S, Dahiya D, Duseja A, Vyas S, Saini V. External stenting of pancreaticojejunostomy anastomosis and pancreatic duct after pancreaticoduodenectomy. Updates Surg. 2012; 64:257-64.
68.Vyas S, Mahajan D, Sandhu MS, Duseja A, Khandelwal N. Portal vein aneurysm: is it an incidental finding only? Ann Hepatol. 2012; 11:263-4.
69.Choudhary N, Duseja A, Kalra N, Chawla Y. Hepatobiliary and Pancreatic: Intrahepatic biloma after blunt abdominal trauma. J Gastroenterol Hepatol. 2011; 26:1342.
70.Tohra SK, Taneja S, Ghosh S, Sharma BK, Duseja A, Dhiman RK, Das A, Chawla YK. Prediction of Sustained Virological Response to Combination Therapy with Pegylated Interferon Alfa and Ribavirin in Patients with Genotype 3 Chronic Hepatitis C. Dig Dis Sci. 2011 ;56:3449-55.
71.Menachery J, Duseja A. Treatment of decompensated alcoholic liver disease. Int J Hepatol. 2011;2:219-238
72.Ghosh S, Duseja A, Dhiman RK, Chawla YK. Tongue Hyperpigmentation Resulting from Peginterferon Alfa-2b and Ribavirin Treatment in a Patient with Chronic Hepatitis C. Dig Dis Sci. 2011; 57:820-1.
73.Choudhary NS, Tomar M, Chawla YK, Bhadada SK, Khandelwal N, Dhiman RK, Duseja A, Bhansali A. Hepatic Osteodystrophy Is Common in Patients with Noncholestatic Liver Disease. Dig Dis Sci. 2011; 56:3323-7.
74.Menachery J, Chawla Y, Duseja A, Dhiman RK, Kalra N, Vankar S. Retroduodenal perforation without sphincterotomy: a case report. Dig Dis Sci. 2011; 56:610-1.
75.Duseja A, Sharma B, Kumar A, Kapil S, Das A, Dhiman RK, Chawla YK. Nonalcoholic fatty liver in a developing country is responsible for significant liver disease. Hepatology. 2010; 52:2248-9.
76.Duseja A, Chawla YK, Dhiman RK, Kumar A, Choudhary N, Taneja S. Non-hepatic Insults Are Common Acute Precipitants in Patients with Acute on Chronic Liver Failure (ACLF). Dig Dis Sci. 2010; 55:3188-92.
77.Taneja S, Kalra N, Duseja A, Dhiman RK. Noncirrhotic portal fibrosis and abdominal varices. Liver Int. 2010; 30:715-7.
78.Saikia UN, Sharma N, Duseja A, Bhalla A, Joshi K. Anaplastic large cell lymphoma presenting as acute liver failure: A report of two cases with review of literature. Ann Hepatol. 2010; 9:457-61.
79.Sachdeva A, Bhalla A, Sood A, Duseja A, Gupta V. The effect of sedation during upper gastrointestinal endoscopy. Saudi J Gastroenterol. 2010; 16:280-4.
80.Sharma B, Srinivasan R, Chawla YK, Kapil S, Saini N, Singla B, Chakraborthy A, Kalra N, Duseja A, Dhiman RK. Clinical utility of prothrombin induced by vitamin K absence in the detection of hepatocellular carcinoma in Indian population. Hepatol Int. 2010; 4:569-76.
81.Gupta A, Dhiman RK, Kumari S, Rana S, Agarwal R, Duseja A, Chawla Y. Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. J Hepatol. 2010 ;53:849-55.
82.Dhiman RK, Saraswat VA, Sharma BK, Sarin SK, Chawla YK, Butterworth R, Duseja A, Aggarwal R, Amarapurkar D, Sharma P, Madan K, Shah S, Seth AK, Gupta RK, Koshy A, Rai RR, Dilawari JB, Mishra SP, Acharya SK; Indian National Association for Study of the Liver.
Minimal hepatic encephalopathy: consensus statement of a working party of the Indian National Association for Study of the Liver. J Gastroenterol Hepatol. 2010 ;25:1029-41.
83.Dhiman RK, Kurmi R, Thumburu KK, Venkataramarao SH, Agarwal R, Duseja A, Chawla Y. Diagnosis and prognostic significance of minimal hepatic encephalopathy in patients with cirrhosis of liver. Dig Dis Sci. 2010; 55:2381-90.
84.Sharma S, Sharma B, Singla B, Chawla YK, Chakraborti A, Saini N, Duseja A, Das A, Dhiman RK. Clinical significance of genotypes and precore/basal core promoter mutations in HBV related chronic liver disease patients in North India. Dig Dis Sci. 2010; 55:794-802
85.Duseja A, Dhiman RK, Chawla Y, Thumburu KK, Kumar A, Das A, Bhadada S, Bhansali A. Insulin resistance is common in patients with predominantly genotype 3 chronic hepatitis C. Dig Dis Sci. 2009; 54:1778-82.
86.Duseja A, Das A, Chawla YK, Bhansali A, Sakhuja V. Clinicopathological conference: fibrosing cholestatic hepatitis presenting as subacute hepatic failure in a non-transplant patient. Dig Dis Sci. 2009; 54:2341-5.
87.Chawla Y, Duseja A, Dhiman RK. Review article: the modern management of portal vein thrombosis. Aliment Pharmacol Ther. 2009; 30:881-94.
88.Kalra N, Duseja A, Das A, Dhiman RK, Virmani V, Chawla Y, Singh P, Khandelwal N. Chemical shift magnetic resonance imaging is helpful in detecting hepatic steatosis but not fibrosisin patients with nonalcoholic fatty liver disease (NAFLD). Ann Hepatol. 2009; 8:21-5.
89.Kalra N, Gulati A, Khandelwal N, Duseja A, Behra A, Joshi K. Pitfall in the diagnosis of biliary ascariasis. J Clin Ultrasound. 2009 ;62:161-2
90.Chawla Y, Duseja A. Intrahepatic stones: is it a lifestyle disease? J Gastroenterol Hepatol. 2008; 23:998-9.
91.Das K, Singh P, Chawla Y, Duseja A, Dhiman RK, Suri S. Magnetic resonance imaging of brain in patients with cirrhotic and non-cirrhotic portal hypertension. Dig Dis Sci. 2008; 53:2793-8.
92.Gupta R, Chettri D, Sharma A, Duseja A, Dhiman RK, Chawla YK, Kalra N, Gupta A, Behera A. Pancreatic cysts causing biliary obstruction in von Hippel Lindau syndrome. JOP. 2008; 9:313-6.
93.Das K, Singh P, Chawla Y, Duseja A, Dhiman RK, Suri S. Magnetic resonance imaging of brain in patients with cirrhotic and non-cirrhotic portal hypertension. Dig Dis Sci. 2008; 53:2793-8.
94.Duseja A, Das A, Dhiman RK, Chawla YK, Thumburu KT, Bhadada S, Bhansali A.  Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions. Ann Hepatol 2007; 6:222-6.
95.Duseja A, Das A, Das R, Dhiman RK, Chawla Y, Bhansali A, Kalra N. Clinicopathological profile of Indian patients with nonalcoholic fatty liver disease is different from that in the west. Dig Dis Sci 2007; 52:2368-74.
96.Duseja A, Das A, Dhiman RK, Chawla YK, Das R, Bhadada S, Sialy R, Thumburu KK, Bhansali A, Kalra N. Indian patients with nonalcoholic fatty liver disease presenting with raised transaminases are different at presentation. World J Gastroenterol 2007;13:649-5
97.Dhiman RK, Duseja A, Chawla YK.  Reply: Prognostic impact of lactate in acute liver failure. Liver Transpl. 2007; 14:123.
98.Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology. 2007; 45:549-59.
99.Dhiman RK, Jain S, Maheshwari U, Bhalla A, Sharma N, Ahluwalia J, Duseja A, Chawla Y.  Early indicators of prognosis in fulminant hepatic failure: an assessment of the Model for End-Stage Liver Disease (MELD) and King's College Hospital criteria. Liver Transpl. 2007; 13:814-21.
100.Dhillon BK, Das R, Garewal G, Chawla Y, Dhiman RK, Das A, Duseja A, Chandak GR.  Frequency of primary iron overload and HFE gene mutations (C282Y, H63D and S65C) in chronic liver disease patients in north India. World J Gastroenterol. 2007; 13:2956-9.
101.Duseja A, Das R, Das A, Dhiman RK, Chawla Y, Garewal G. Serum iron and hepatic iron overload in patients with nonalcoholic steatohepatitis. Dig Dis Sci 2006 ;51:1730-1
102.Sharma S, Saini N, Arora L, Chawla Y, Duseja A. Prolonged Hepatitis B surface antigen positivity in Hepatitis B vaccine recipients. Dig Liver Dis. 2006;38:860-1
103.Saini N,  Bhagat A,  Sharma S, Duseja A, Chawla Y. Evaluation of clinical and biochemical parameters in hepatocellular carcinoma: Experience from an Indian center. Clin Chim Acta. 2006 ;371:183-6
104.Bhalla A, Sachdev A, Sood A, Duseja A, Gupta V. Cardiorespiratory compromise under conscious sedation during upper gastrointestinal endoscopy. J Coll Physicians Surg Pak. 2006; 16:585-9.
105.Duseja A, Das R, Nanda M, Das A, Garewal G, Chawla Y Nonalcoholic steatohepatitis in Asian Indians is neither associated with iron overload nor with HFE gene mutations. World J Gastroenterol 2005; 11:393-5.
106.Duseja A, Nada R, Dhiman RK, Chawla YK, Kalra N, Prashad S, Karwasra RK. Eosinophilic Cholangiopathy – A case report. Dig Dis & Sci 2005; 50: 1422-1425
107.Duseja A, Jain P, Reddy CS, Sharma TR, Dhiman RK, Chawla Y. Safety and Efficacy of ERCP in pregnancy. Gastrointest Endosc 2005; 61:352-353
108.Dhiman RK, Duseja A, Chawla Y. Asians need different criteria for defining obesity. Arch Intern Med 2005; 165:1069-70.
109.Sachdev A, Duseja A, Nada R, Mohan H, Bhalla A. An unusual cause of malabsorption in an immunocompetent host. JAMC. 2005; 17:85-86.
110.Marwaha RK, Bansal D, Sharma S, Kumar S, Trehan A, Duseja A, Chawla YK. Seroprevalence of hepatitis C and B virus in multiply transfused beta-thalassemics: results from a thalassemic day care unit in north India. Vox Sang. 2003; 85:119-120
111.R Sidhu, A Dabra, Duseja A. Intrathoracic kidney in an adult. Urol Int 2001; 66:174-5
112.Duseja A, YK Chawla, R Singh et al. Dilatation of benign oesphagal strictures. 10 years experience with Celestin Dilators. J Gastroenterol Hepatol 2000; 15:26-29
Chapters in a Book- 22   
1.De A, Duseja A. Nonalcoholic Fatty Liver Disease – How Do I Manage? Progress in Gastroenterology and Hepatology 2019, Bhat N, Anand AC Eds, Thieme, 179-184, 2019
2.Duseja A. Non – alcoholic Fatty Liver Disease. In: API Textbook of Medicine 11th ed, Munjal YP, ed. N Delhi: JP Publishers Pvt Ltd; 2018, 1791-95.
3.Satsangi S, Duseja A. NASH: do we really have an effective treatment? -  Medicine Update, API Publishers 2017.
4.Gupta T, Duseja A. How should I manage non-alcoholic fatty liver disease in 2016? – Progress in Gastroenterology and Hepatology 2016, Elsevier
5.Agrawal S, Duseja A. Non-Alcoholic fatty Liver Disease (NAFLD)- Epidemiology and risk factors – Macmillan publishers [India] Group of Nature Publications, 2015.
6.Duseja A. Non – alcoholic Fatty Liver Disease. In: API Textbook of Medicine 10th ed, Munjal YP, ed. N Delhi: JP Publishers Pvt Ltd; 1199–03, 2015. 

7.Choudhary N, Duseja A. Hepatitis B virus. In : Textbook of Gasteroenterology & Hepatology first ed, Hasan M,Akbar SM, Mehtab MA, ed. N Delhi: JP Publishers Pvt Ltd;164 – 75, 2015.
8.Bodh V, Duseja A, Chawla Y. Hepatitis C vaccine. In: Adult immunization second ed, Muruganathan A, Mathai D, Sharma SK, ed. Mumbai : JP Publishers Pvt Ltd; 64 -72, 2015.
9.Agrawal S, Duseja A. Non – Alcoholic fatty liver disease (NAFLD) - Frequently asked questions. In: Monograph on Non Alcoholic Steatohepatitis (NASH), Kumar A, ed. N Delhi: Association of physicians of India; 170-78, 2015.
10.Agrawal S, Duseja A. NAFLD – in India – Is it different from the west? In : Monograph on Non Alcoholic Steatohepatitis (NASH), Kumar A, ed. N Delhi: Association of physicians of India; 62-69, 2015.
11.Duseja A. Non – Alcoholic fatty liver disease. In: Medicine Update 25 ed, Upadhyaya R, ed. N Delhi:  Association of physicians of India; 371 – 6, 2015.
12.Sakpal M, Duseja A. Acute viral hepatitis in elderly. In: Textbook of Geriatric Medicine first ed, Sanchetee P, ed. N Delhi: Paras Medical Publishers; 377 – 81, 2014.
13.Choudhary NS, Duseja A. Hepatitis B Virus  – Text Book of Hepato-Gastroenterology, Jaypee Brothers, 2012
14.Ghosh S, Duseja A. Interpretation of Liver Function Tests – INASL Text book of Liver Diseases, 2011
15.Agrawal S, Duseja A. Mechanisms of fat accumulation and liver injury - Elsevier ECAB, 2011
16.Chawla YK, Duseja A. Extrahepatic portal venous obstruction. Tropical Hepatogastroenterology. 2008; 404-412. published by Elsevier, Reed Elsevier India Private Limited
17.Duseja A. Bacterial cholangitis. In, Gastointestinal Tract Infections. 2008; 416-24. Published by Paragon International Publishers
18.Duseja A. What is the role of intracranial pressure monitoring in management of acute liver failure? In- 100 clinical questions in Gastroenterology. Eds Ajay Kumar, Manav Wadhavan. 2007; 17-19
19.Duseja A. Endoscopic management of oesophageal varices. (Eds Mahesh K Goenka, Pradeepta K Sethy). In Gastrointestinal Endoscopy and Interventions: A Review  2005; 5-14
20.Dhiman RK, Duseja A. Nonalcoholic Fatty Liver Disease. In. J Assoc Physicians India. Medicine Update. Eds. SB Gupta. 2005; 15: pp 469-75.
21.Duseja A. Management of cholangitis. In Current Perspectives in Gastrointestinal Endoscopy.  Eds. D Nageshwar Reddy, GV Rao. 2004: 90-94
22.Duseja A, Chawla Y. Modes of transmission of hepatitis B virus. In Hepatitis B in India: Prevention and Management Eds. SK Sarin, AK Singal 2004; 15-21.
Research Area of interest – Non-alcoholic fatty liver disease (NAFLD)
NAFLD publications – 56 (Including 11 chapters in a book
1.Duseja A, Najmy S, Sachdev S, Pal A, Sharma RR, Marwah N, Chawla Y. High prevalence of non-alcoholic fatty liver disease among healthy male blood donors of urban India. JGH Open. 2019 Jan 16;3(2):133-139.
2.Nampoothiri RV, Duseja A, Rathi M, et al. Renal Dysfunction in Patients With Nonalcoholic Fatty Liver Disease is Related to the Presence of Diabetes Mellitus and Severity of Liver Disease. J Clin Exp Hepatol. 2019;9:22-28.
3.Chan WK, Treeprasertsuk S, Goh GB, Fan JG, Song MJ, Charatcharoenwitthaya P, Duseja A, et al. Optimizing Use of Nonalcoholic Fatty Liver Disease Fibrosis Score, Fibrosis-4 Score, and Liver Stiffness Measurement to Identify Patients with Advanced Fibrosis. Clin Gastroenterol Hepatol. 2019 Mar 12. [Epub ahead of print]
4.Sakpal M, Satsangi S, Mehta M, Duseja A, Bhadada S, Das A, Dhiman RK, Chawla YK. Vitamin D supplementation in patients with nonalcoholic fatty liver disease: A randomized controlled trial. JGH Open. 2017 ; 2:62-67.
5.Younossi ZM, Stepanova M, Ong J, Yilmaz Y, Duseja A, Eguchi Y, El Kassas M,Castellanos-Fernandez M, George J, Jacobson IM, Bugianesi E, Wai-Sun Wong V,Arrese M, de Ledinghen V, Romero-Gomez M, Mendez-Sanchez N, Ahmed A, Wong R,Papatheodoridis G, Serfaty L, Younossi I, Nader F, Ziayee M, Afendy A; Global NASH Council.
Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients with Non-alcoholic and Alcohol-Related Fatty Liver Disease. Clin Gastroenterol Hepatol. 2018 ; 23.[Epub ahead of print]
6.Molnar MZ, Joglekar K, Jiang Y, Cholankeril G, Abdul MKM, Kedia S, Gonzalez,HC, Ahmed A, Singal A, Bhamidimarri KR, Aithal GP, Duseja A, Wong VW, Gulnare A, Puri P, Nair S, Eason JD, Satapathy SK; Global NAFLD Consortium. Association of Pre-Transplant Renal Function with Liver Graft and Patient Survival
after Liver Transplantation in Patients with Nonalcoholic Steatohepatitis. Liver Transpl. 2018 ; 28. [Epub ahead of print]
7.Younossi Z, Stepanova M, Ong JP, Jacobson IM, Bugianesi E, Duseja A, Eguchi Y,Wong VW, Negro F, Yilmaz Y, Romero-Gomez M, George J, Ahmed A, Wong R, Younossi I, Ziayee M, Afendy A; Global Nonalcoholic Steatohepatitis Council. Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular
Carcinoma in Liver Transplant Candidates. Clin Gastroenterol Hepatol. 2018;14. [Epub ahead of print]
8.Chitturi S, Wong VW, Chan WK, Wong GL, Wong SK, Sollano J, Ni YH, Liu CJ, Lin YC, Lesmana LA, Kim SU, Hashimoto E, Hamaguchi M, Goh KL, Fan J, Duseja A et.al. The Asia-Pacific Working Party on Nonalcoholic Fatty Liver Disease Guidelines 2017 Part 2: Management and special groups. J Gastroenterol Hepatol. 2018 ; 1: 86-98.
9.Wong VW, Chan WK, Chitturi S, Chawla Y, Dan YY, Duseja A et.al. The Asia-Pacific Working Party on Nonalcoholic Fatty Liver Disease Guidelines 2017 Part 1: Definition, risk factors and assessment. J Gastroenterol Hepatol. 2018;1:70-85.
10.Mehta M,  Satsangi S,  Duseja A, Taneja S,  Dhiman RK, Chawla Y. Can Alcoholic Liver Disease and Nonalcoholic Fatty Liver Disease Co-Exist? J Clin Exp Hepatol. 2017 ;2:121-126
11.Choudhary NS, Saraf N, Saigal S, Duseja A, Gautam D, Lipi L, Rastogi A, Goja S, Bhangui P, Ramchandra SK, Babu YR, Soin AS. Prediction of nonalcoholic fatty liver in prospective liver donors. Clin Transplant. 2016 ;17. [Epub ahead of print]
12.Kapil S, Duseja A, Sharma BK, Singla B, Chakraborti A, Das A, Ray P, Dhiman RK, Chawla Y. Genetic polymorphism in CD14 gene, a co-receptor of TLR4 associated with non-alcoholic fatty liver disease. World J Gastroenterol. 2016; 42:9346-9355.
13.Kapil S, Duseja A, Sharma BK, Singla B, Chakraborti A, Das A, Ray P, Dhiman RK, Chawla Y. Small intestinal bacterial overgrowth and toll-like receptor signaling in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2016; 31:213-21.
14.Duseja A, Singh SP, Saraswat VA, Acharya SK, Chawla YK, Chowdhury S, Dhiman RK, Jayakumar RV et.al. Non-alcoholic Fatty Liver Disease and Metabolic Syndrome-Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology.
J Clin Exp Hepatol. 2015; 5:51-68.
15.Agrawal S, Duseja A, Aggarwal A, Das A, Mehta M, Chawla Y et.al. Obstructive sleep apnea is an important predictor of hepatic fibrosis in patients with nonalcoholic fatty liver disease in a tertiary care center. Hepatol Int. 2015; 9:283-91.
16.Duseja A, Chawla YK. Obesity and NAFLD: the role of bacteria and microbiota. Clin Liver Dis. 2014 ;18:59-71
17.Duseja A, Chalasani N. Epidemiology and risk factors of non-alcoholic fatty liver disease (NAFLD). Hepato Int 2013; 7: S755 – S764.
18.Guleria A, Duseja A, Kalra N, Das A, Dhiman R, Chawla Y, Bhansali A. Patients with non-alcoholic fatty liver disease (NAFLD) have an increased risk of atherosclerosis and cardiovascular disease. Trop Gastroenterol. 2013; 34:74-82.
19.Duseja A, Aggarwal R. APOC3 and PNPLA3 in Non-alcoholic Fatty Liver Disease (NAFLD) - Need to Clear the Am. J Gastroenterol Hepatol. 2012; 27:848-51.
20.Choudhary NS, Duseja A, Kalra N, Das A, Dhiman RK, Chawla YK.  Correlation of adipose tissue with liver histology in Asian Indian patients with nonalcoholic fatty liver disease (NAFLD). Ann Hepatol. 2012; 11:478-86.
21.Kumar A, Sharma A, Duseja A, Das A, Dhiman RK, Chawla Y. Patients with Nonalcoholic Fatty Liver Disease (NAFLD) have Higher Oxidative Stress in Comparison to Chronic Viral Hepatitis. J Clin Exp Hepatol 2012:2:12-18
22.Rana D, Duseja A, Dhiman RK, Chawla Y and Arora SK. Maturation defective myeloid dendritic cells in nonalcoholic fatty liver disease patients release inflammatory cytokines in response to endotoxin.  Hepatol Int 2012; 7:562-9.
23.Agrawal S, Duseja A. Non-alcoholic Fatty Liver Disease: East versus West. J Clin & Exp Hepatol 2012; 2: 122-134
24.Duseja A. It is Patatin - like Phospholipase Domain- Containing 3 gene (PNPLA3) – All the way. J Clin Exp Hepatol 2011; 2:94-96.
25.Duseja A, Sharma B, Kumar A, et al. Nonalcoholic fatty liver in a developing country is responsible for significant liver disease. Hepatology. 2010; 52:2248-9.
26.Duseja A. Nonalcoholic fatty liver disease in India - a lot done, yet more required! Indian J Gastroenterol. 2010; 29:217-25
27.Duseja A, Dhiman RK, Chawla Y, Thumburu KK, Kumar A, Das A, Bhadada S, Bhansali A. Insulin resistance is common in patients with predominantly genotype 3 chronic hepatitis C. Dig Dis Sci. 2009; 54:1778-82.
28.Kalra N, Duseja A, Das A, Dhiman RK, Virmani V, Chawla Y, Singh P, Khandelwal N. Chemical shift magnetic resonance imaging is helpful in detecting hepatic steatosis but not fibrosis in patients with nonalcoholic fatty liver disease (NAFLD). Ann Hepatol. 2009; 8:21-5.
29.Das A, Duseja A. Liver pathology in nonalcoholic fatty liver disease. Ann Natl  Acad Med Sci  2008;44:87-95
30.Duseja A, Das A, Das R, Dhiman RK, Chawla Y, Bhansali A, Kalra N. Clinicopathological profile of Indian patients with nonalcoholic fatty liver disease is different from that in the west. Dig Dis Sci 2007; 52:2368-74.
31.Duseja A, Das A, Dhiman RK, Chawla YK, Thumburu KT, Bhadada S, Bhansali A.  Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions. Ann Hepatol 2007; 6:222-6.
32.Duseja A, Das A, Dhiman RK, Chawla YK, Das R, Bhadada S, Sialy R, Thumburu KK, Bhansali A, Kalra N. Indian patients with nonalcoholic fatty liver disease presenting with raised transaminases are different at presentation. World J Gastroenterol 2007;13:649-50
33.Duseja A, Thumburu KK, Das A, Dhiman RK, Chawla YK, Bhadada S, Bhansali A.  Insulin tolerance test is comparable to homeostasis model assessment for insulin resistance in patients with nonalcoholic fatty liver disease. Indian J Gastroenterol. 2007; 26:170-3.
34.Duseja A, Kalra N, Chawla YK: Clinical Spectrum and Diagnosis of Nonalcoholic Fatty Liver Disease. Ann Natl  Acad Med Sci  2007; 43:167-182.
35.Duseja A:  Molecular Targets for Therapeutic Intervention in patients with Nonalcoholic Fatty Liver Disease. Ann Natl  Acad Med Sci   2007; 43:183-190.
36.Duseja A. Nonalcoholic fatty liver disease in India- Is it different? Trop Gastroenterol 2006 ;27:142-6
37.Duseja A, Das R, Das A, Dhiman RK, Chawla Y, Garewal G. Serum iron and hepatic iron overload in patients with nonalcoholic steatohepatitis. Dig Dis Sci 2006 ;51:1730-1
38.Duseja A, Das R, Nanda M, Das A, Garewal G, Chawla Y Nonalcoholic steatohepatitis in Asian Indians is neither associated with iron overload nor with HFE gene mutations. World J Gastroenterology 2005; 21:11:393-5.
39.Duseja A, Das A, Das R, Dhiman RK, Chawla Y, Bhansali A. Unconjugated hyperbilirubinemia in nonalcoholic steatohepatitis – Is it Gilbert’s syndrome? Tropical Gastroenterology 2005; 26:123-25.
40.Duseja A, Chawla Y. Nonalcoholic fatty liver disease in India- How much? How soon? Tropical Gastroenterology 2005; 26: 1-3.
41.Duseja A, Dhiman RK. Nonalcoholic fatty liver disease. Gastroenterology Today 2005;9:145-149.
42.Dhiman RK, Duseja A, Chawla Y. Asians need different criteria for defining obesity. Archives of Internal Medicine 2005; 165:1069-70.
43.Duseja A, Murlidharan R, Bhansali A, Sharma S, Das A, Das R, Chawla Y. Assessment of insulin resistance and effect of metformin in nonalcoholic steatohepatitis- A preliminary report. Indian J Gastroenterol 2004; 23:12-15
44.Duseja A, Mohit Nanda, Ashim Das, Reena Das, Anil Bhansali, Yogesh Chawla. Prevalence of obesity, diabetes mellitus and hyperlipidemia in patients with cryptogenic liver cirrhosis. Trop Gastroenterol 2004; 25:15-17.
45.Duseja A, Dhiman RK. Nonalcoholic steatohepatitis (NASH) – How much fat in Indian livers? Bull PGI 2003; 37:44-47.
NAFLD Chapters in a book - 11
1.De A, Duseja A. Nonalcoholic Fatty Liver Disease – How Do I Manage? Progress in Gastroenterology and Hepatology 2019, Bhat N, Anand AC Eds, Thieme, 179-184, 2019
2.Duseja A. Non–alcoholic Fatty Liver Disease. In: API Textbook of Medicine 11th ed, Munjal YP, ed. N Delhi: JP Publishers Pvt Ltd; 2018, 1791-95.
3.Satsangi S, Duseja A. NASH: do we really have an effective treatment?-  Medicine Update, API Publishers 2017.
4.Gupta T, Duseja A. How should I manage non-alcoholic fatty liver disease in 2016? – Progress in Gastroenterology and Hepatology 2016 Elsevier
5.Duseja A. Non – alcoholic Fatty Liver Disease. In: API Textbook of Medicine 10th ed, Munjal YP, ed. N Delhi: JP Publishers Pvt Ltd; 2015, 1199–03.
6.Duseja A. Nonalcoholic fatty liver disease. In: Medicine Update 25 ed, Upadhyaya R, ed. N Delhi:  Association of physicians of India; 371 – 6, 2015.
7.Agrawal S, Duseja A. Non – Alcoholic fatty liver disease (NAFLD) - Frequently asked questions. In: Monograph on Non Alcoholic Steatohepatitis (NASH), Kumar A, ed. N Delhi: Association of physicians of India; 170-78, 2015.
8.Agrawal S, Duseja A. NAFLD – in India – Is it different from the west? In : Monograph on Non Alcoholic Steatohepatitis (NASH), Kumar A, ed. N Delhi: Association of physicians of India; 62-69, 2015.
9.Agrawal S, Duseja A. Nonalcoholic Fatty Liver Disease (NAFLD) - Epidemiology and Risk Factors' - Macmillan publishers [India]Group of Nature publications, 2012
10.Agrawal S, Duseja A. Mechanisms of fat accumulation and liver injury - Elsevier ECAB, 2011
11.Dhiman RK, Duseja A. Nonalcoholic Fatty Liver Disease. In. J Assoc Physicians India. Medicine Update. Eds. SB Gupta. 2005; 15: pp 469-75.